250 related articles for article (PubMed ID: 31287994)
1. Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia.
Baccelli I; Gareau Y; Lehnertz B; Gingras S; Spinella JF; Corneau S; Mayotte N; Girard S; Frechette M; Blouin-Chagnon V; Leveillé K; Boivin I; MacRae T; Krosl J; Thiollier C; Lavallée VP; Kanshin E; Bertomeu T; Coulombe-Huntington J; St-Denis C; Bordeleau ME; Boucher G; Roux PP; Lemieux S; Tyers M; Thibault P; Hébert J; Marinier A; Sauvageau G
Cancer Cell; 2019 Jul; 36(1):84-99.e8. PubMed ID: 31287994
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel toxicophore in anti-cancer chemotherapeutics that targets mitochondrial respiratory complex I.
Stephenson ZA; Harvey RF; Pryde KR; Mistry S; Hardy RE; Serreli R; Chung I; Allen TE; Stoneley M; MacFarlane M; Fischer PM; Hirst J; Kellam B; Willis AE
Elife; 2020 May; 9():. PubMed ID: 32432547
[TBL] [Abstract][Full Text] [Related]
3. Targeting mitochondrial RNA polymerase in acute myeloid leukemia.
Bralha FN; Liyanage SU; Hurren R; Wang X; Son MH; Fung TA; Chingcuanco FB; Tung AY; Andreazza AC; Psarianos P; Schimmer AD; Salmena L; Laposa RR
Oncotarget; 2015 Nov; 6(35):37216-28. PubMed ID: 26484416
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.
Farge T; Saland E; de Toni F; Aroua N; Hosseini M; Perry R; Bosc C; Sugita M; Stuani L; Fraisse M; Scotland S; Larrue C; Boutzen H; Féliu V; Nicolau-Travers ML; Cassant-Sourdy S; Broin N; David M; Serhan N; Sarry A; Tavitian S; Kaoma T; Vallar L; Iacovoni J; Linares LK; Montersino C; Castellano R; Griessinger E; Collette Y; Duchamp O; Barreira Y; Hirsch P; Palama T; Gales L; Delhommeau F; Garmy-Susini BH; Portais JC; Vergez F; Selak M; Danet-Desnoyers G; Carroll M; Récher C; Sarry JE
Cancer Discov; 2017 Jul; 7(7):716-735. PubMed ID: 28416471
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia sensitivity to metabolic inhibitors: glycolysis showed to be a better therapeutic target.
Lapa B; Gonçalves AC; Jorge J; Alves R; Pires AS; Abrantes AM; Coucelo M; Abrunhosa A; Botelho MF; Nascimento-Costa JM; Sarmento-Ribeiro AB
Med Oncol; 2020 Jul; 37(8):72. PubMed ID: 32725458
[TBL] [Abstract][Full Text] [Related]
6. Berberine targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia with IDH1 mutation.
Huang Z; Shen Y; Liu W; Yang Y; Guo L; Yan Q; Wei C; Guo Q; Fan X; Ma W
Chin J Nat Med; 2023 Feb; 21(2):136-145. PubMed ID: 36871981
[TBL] [Abstract][Full Text] [Related]
7. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
8. Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells.
Larrue C; Guiraud N; Mouchel PL; Dubois M; Farge T; Gotanègre M; Bosc C; Saland E; Nicolau-Travers ML; Sabatier M; Serhan N; Sahal A; Boet E; Mouche S; Heydt Q; Aroua N; Stuani L; Kaoma T; Angenendt L; Mikesch JH; Schliemann C; Vergez F; Tamburini J; Récher C; Sarry JE
Nat Commun; 2021 Jan; 12(1):422. PubMed ID: 33462236
[TBL] [Abstract][Full Text] [Related]
9. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
[TBL] [Abstract][Full Text] [Related]
10. Targeting mitochondrial respiration for the treatment of acute myeloid leukemia.
Carter JL; Hege K; Kalpage HA; Edwards H; Hüttemann M; Taub JW; Ge Y
Biochem Pharmacol; 2020 Dec; 182():114253. PubMed ID: 33011159
[TBL] [Abstract][Full Text] [Related]
11. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial metabolism: powering new directions in acute myeloid leukemia.
Stubbins RJ; Maksakova IA; Sanford DS; Rouhi A; Kuchenbauer F
Leuk Lymphoma; 2021 Oct; 62(10):2331-2341. PubMed ID: 34060970
[TBL] [Abstract][Full Text] [Related]
13. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
Xu B; Zhao Y; Wang X; Gong P; Ge W
Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
[TBL] [Abstract][Full Text] [Related]
14. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
[TBL] [Abstract][Full Text] [Related]
15. Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia.
Di Marcantonio D; Martinez E; Sidoli S; Vadaketh J; Nieborowska-Skorska M; Gupta A; Meadows JM; Ferraro F; Masselli E; Challen GA; Milsom MD; Scholl C; Fröhling S; Balachandran S; Skorski T; Garcia BA; Mirandola P; Gobbi G; Garzon R; Vitale M; Sykes SM
Clin Cancer Res; 2018 Feb; 24(3):608-618. PubMed ID: 29127121
[No Abstract] [Full Text] [Related]
16. Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.
Liyanage SU; Hurren R; Voisin V; Bridon G; Wang X; Xu C; MacLean N; Siriwardena TP; Gronda M; Yehudai D; Sriskanthadevan S; Avizonis D; Shamas-Din A; Minden MD; Bader GD; Laposa R; Schimmer AD
Blood; 2017 May; 129(19):2657-2666. PubMed ID: 28283480
[TBL] [Abstract][Full Text] [Related]
17. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains.
Rzymski T; Mikula M; Żyłkiewicz E; Dreas A; Wiklik K; Gołas A; Wójcik K; Masiejczyk M; Wróbel A; Dolata I; Kitlińska A; Statkiewicz M; Kuklinska U; Goryca K; Sapała Ł; Grochowska A; Cabaj A; Szajewska-Skuta M; Gabor-Worwa E; Kucwaj K; Białas A; Radzimierski A; Combik M; Woyciechowski J; Mikulski M; Windak R; Ostrowski J; Brzózka K
Oncotarget; 2017 May; 8(20):33779-33795. PubMed ID: 28422713
[TBL] [Abstract][Full Text] [Related]
18. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia.
Boros K; Puissant A; Back M; Alexe G; Bassil CF; Sinha P; Tholouli E; Stegmaier K; Byers RJ; Rodig SJ
Oncotarget; 2015 Sep; 6(28):25575-87. PubMed ID: 26315286
[TBL] [Abstract][Full Text] [Related]
19. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
20. SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias.
Bourrié B; Brassard DL; Cosnier-Pucheu S; Zilberstein A; Yu K; Levit M; Morrison JG; Perreaut P; Jegham S; Hilairet S; Bouaboula M; Penarier G; Guiot C; Larroze-Chicot P; Laurent G; Demur C; Casellas P
Leuk Lymphoma; 2013 Jul; 54(7):1488-99. PubMed ID: 23121564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
